SG11202110964QA - Anti-vegf protein compositions and methods for producing the same - Google Patents

Anti-vegf protein compositions and methods for producing the same

Info

Publication number
SG11202110964QA
SG11202110964QA SG11202110964QA SG11202110964QA SG11202110964QA SG 11202110964Q A SG11202110964Q A SG 11202110964QA SG 11202110964Q A SG11202110964Q A SG 11202110964QA SG 11202110964Q A SG11202110964Q A SG 11202110964QA SG 11202110964Q A SG11202110964Q A SG 11202110964QA
Authority
SG
Singapore
Prior art keywords
producing
methods
same
protein compositions
vegf protein
Prior art date
Application number
SG11202110964QA
Other languages
English (en)
Inventor
Andrew Tustian
Ankit Vartak
Thomas Daly
Erica Pyles
Nisha Palackal
Shunhai Wang
Ning Li
Original Assignee
Regeneron Pharmacetucals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76210828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202110964Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmacetucals Inc filed Critical Regeneron Pharmacetucals Inc
Publication of SG11202110964QA publication Critical patent/SG11202110964QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/80—Fraction collectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SG11202110964QA 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same SG11202110964QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944635P 2019-12-06 2019-12-06
US202063065012P 2020-08-13 2020-08-13
PCT/US2020/046809 WO2021112923A1 (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Publications (1)

Publication Number Publication Date
SG11202110964QA true SG11202110964QA (en) 2021-10-28

Family

ID=76210828

Family Applications (6)

Application Number Title Priority Date Filing Date
SG11202110953UA SG11202110953UA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110955VA SG11202110955VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110958QA SG11202110958QA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110968VA SG11202110968VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110964QA SG11202110964QA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110972UA SG11202110972UA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Family Applications Before (4)

Application Number Title Priority Date Filing Date
SG11202110953UA SG11202110953UA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110955VA SG11202110955VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110958QA SG11202110958QA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110968VA SG11202110968VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202110972UA SG11202110972UA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Country Status (18)

Country Link
US (34) US11104715B2 (ko)
EP (6) EP3906249A1 (ko)
JP (12) JP2022550930A (ko)
KR (12) KR102519236B1 (ko)
CN (6) CN114206924A (ko)
AU (12) AU2020398830C1 (ko)
BR (5) BR112022001016A2 (ko)
CA (4) CA3159586A1 (ko)
CO (6) CO2021018181A2 (ko)
IL (16) IL302921A (ko)
MX (10) MX2021014862A (ko)
MY (12) MY193351A (ko)
NZ (6) NZ781138A (ko)
PE (6) PE20221770A1 (ko)
SG (6) SG11202110953UA (ko)
TW (6) TW202128744A (ko)
WO (7) WO2021112927A1 (ko)
ZA (4) ZA202107644B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550930A (ja) * 2019-12-06 2022-12-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
WO2022234412A1 (en) 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
WO2023039457A1 (en) * 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
CN116162148A (zh) * 2021-11-24 2023-05-26 苏州光度生物科技有限公司 多特异性配体结合分子及其应用
WO2023137143A1 (en) * 2022-01-14 2023-07-20 Shattuck Labs, Inc. Methods of contaminant removal from protein isolates
WO2023230486A2 (en) * 2022-05-23 2023-11-30 Inhalon Biopharma, Inc. Compositions and methods for inhalable therapeutics
WO2024114799A1 (zh) * 2022-12-01 2024-06-06 信达生物制药(苏州)有限公司 三特异性融合蛋白及其用途
WO2024148276A1 (en) * 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof
KR20240115650A (ko) 2023-01-19 2024-07-26 주식회사 스카이테라퓨틱스 티로신 키나아제 억제제의 무정형 나노 분자회합체와 이를 포함하는 조성물 및 그의 제조방법

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1522343A (en) 1923-05-02 1925-01-06 Thom Clarence Magnetic separator
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
EP0283942B1 (en) 1987-03-24 1992-05-20 W.R. Grace & Co.-Conn. Basal nutrient medium for cell culture
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
AU3374795A (en) * 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
SE519827C2 (sv) 1998-03-30 2003-04-15 Viranative Ab Näringsmedium innehållande metionin samt användning av detta
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
DE60041159D1 (de) * 1999-06-08 2009-01-29 Regeneron Pharma VEGF-Rezeptorchimären zur behandlung von Augenkrankheiten, welche durch vaskuläre Permeabilität charakterisiert sind.
AU2669501A (en) * 1999-11-30 2001-06-12 Smithkline Beecham Plc New use
CN1309735C (zh) 2000-05-26 2007-04-11 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
EP1360314B1 (en) 2001-02-15 2009-01-14 Centocor, Inc. Chemically defined medium for cultured mammalian cells
CA2443493A1 (en) 2001-04-13 2002-10-24 Wyeth Surface proteins of streptococcus pyogenes
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8777906B1 (en) 2002-01-24 2014-07-15 Robin Scott Gray Syringe with inspection window
PL377603A1 (pl) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Poprawa jakości produktu w hodowlach komórek ssaczych do wytwarzania białka
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN100537751C (zh) 2004-05-12 2009-09-09 华东理工大学 一种适合中国仓鼠卵巢细胞培养的无血清培养基
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
AU2005302516A1 (en) 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
HUE027096T2 (en) 2005-03-25 2016-08-29 Regeneron Pharma VEGF antagonist formulations
PL1901773T3 (pl) * 2005-06-09 2012-09-28 Hansa Medical Ab Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
CN1778903A (zh) 2005-09-29 2006-05-31 华东理工大学 一种动物细胞高密度连续灌注培养方法
US20070212770A1 (en) 2006-01-04 2007-09-13 Baxter International Inc. Oligopeptide-free cell culture media
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
WO2007149334A2 (en) 2006-06-16 2007-12-27 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
DK2495307T5 (en) 2006-07-13 2018-07-16 Wyeth Llc Preparation of coagulation factor IX with improved glycosylation pattern
CN101541825B (zh) * 2006-08-28 2013-08-14 阿雷斯贸易股份有限公司 Fc融合蛋白的纯化方法
KR20170021375A (ko) 2006-09-10 2017-02-27 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
RU2518289C2 (ru) 2006-09-13 2014-06-10 Эббви Инк, Способ получения антитела или его фрагмента с подпиткой (варианты)
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
CN101681396A (zh) 2007-04-16 2010-03-24 动量制药公司 限定的糖蛋白产品以及相关方法
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
KR20100038235A (ko) 2007-08-31 2010-04-13 에프. 호프만-라 로슈 아게 글리코실화 프로파일 분석
CN101903401B (zh) * 2007-12-21 2013-06-05 罗切格利卡特公司 抗体的稳定性试验
CN102112509B (zh) 2008-07-31 2013-03-20 国立大学法人京都大学 含有不饱和聚酯树脂和微纤化植物纤维的成型材料
RU2011116319A (ru) 2008-09-26 2012-11-10 Шеринг Корпорейшн (US) Производство высокого титра антител
EP2435577A4 (en) 2009-05-26 2016-04-13 Momenta Pharmaceuticals Inc GLYCOPROTEIN PRODUCTION
EP2445936A1 (en) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
HUE029110T2 (en) 2009-07-31 2017-02-28 Baxalta GmbH Cell culture medium for ADAMTS protein expression
ES2813398T3 (es) * 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
EP2325296A1 (en) 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
JP2014503555A (ja) 2011-01-13 2014-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
EP2697361A1 (en) 2011-04-11 2014-02-19 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
KR101644954B1 (ko) 2011-04-29 2016-08-02 바이오콘 리서치 리미티드 배양 동안 락테이트의 축적을 감소시키는 방법 및 폴리펩타이드를 생산하는 방법
WO2012147053A1 (en) 2011-04-29 2012-11-01 Biocon Research Limited A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
RU2018119112A (ru) 2011-05-27 2018-11-07 Эббви Байотекнолоджи Лтд. Композиции и способы на основе dac hyp
WO2013028330A2 (en) * 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
WO2013054250A1 (en) * 2011-10-10 2013-04-18 Dr Reddy's Laboratories Limited Purification method
EP3578203A1 (en) 2011-10-28 2019-12-11 Integritybio Inc. Protein formulations containing amino acids
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
CN102757496B (zh) * 2012-06-07 2014-06-18 山东泉港药业有限公司 一种抗vegf抗体片段的纯化制备方法
AU2012101678B4 (en) * 2012-07-03 2013-01-24 Novartis Ag Use of device
US9695416B2 (en) * 2012-07-18 2017-07-04 Siemens Healthcare Diagnostics Inc. Method of normalizing biological samples
CN104853763A (zh) * 2012-08-02 2015-08-19 赛诺菲 包含阿柏西普或ziv-阿柏西普的制品
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2722673B1 (en) * 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
US9365314B2 (en) * 2012-11-16 2016-06-14 Owens-Brockway Glass Container Inc. Product and package with a photosensitive use-evident feature
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
CN103146648A (zh) 2013-03-14 2013-06-12 北京京蒙高科干细胞技术有限公司 一种无动物源的淋巴细胞无血清培养基
CA2903596C (en) 2013-03-15 2023-10-03 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
EP4039281A1 (en) * 2013-03-15 2022-08-10 Biomolecular Holdings LLC Hybrid immunoglobulin containing non-peptidyl linkage
CN103773732B (zh) 2013-06-08 2016-05-11 李锋 一种化学成分确定的培养基、其应用及大规模培养哺乳动物细胞的生产工艺
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015058369A1 (en) 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
CN104073464A (zh) 2014-07-08 2014-10-01 西藏天虹科技股份有限责任公司 一种cho细胞无血清培养基及其制备方法
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
KR20240093725A (ko) * 2015-03-12 2024-06-24 메디뮨 엘엘씨 알부민 융합 단백질의 정제 방법
KR101867134B1 (ko) * 2015-03-23 2018-06-12 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
AU2016239662B2 (en) 2015-04-01 2021-12-16 Boehringer Ingelheim International Gmbh Cell culture medium
CN105002242A (zh) 2015-07-23 2015-10-28 苏州康聚生物科技有限公司 用于cho细胞中高效表达重组人促甲状腺激素的无血清培养基及其应用
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EP3334842B1 (en) 2015-08-12 2022-03-02 Novartis AG Methods of treating ophthalmic disorders
JP6950957B2 (ja) * 2015-10-22 2021-10-13 プロテノバ株式会社 イムノグロブリン結合ポリペプチド
MX2018006171A (es) 2015-11-18 2018-12-19 Formycon Ag Jeringa de plastico precargada que contiene un antagonista de vegf.
US10925927B2 (en) * 2015-11-18 2021-02-23 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
CN105368808B (zh) * 2015-11-30 2019-04-30 苏州康聚生物科技有限公司 一种IdeS蛋白酶、其制备方法及应用
MX2018007613A (es) 2015-12-22 2018-09-21 Regeneron Pharma Combinacion de anticuerpos anti proteina 1 de muerte celular (pd1) y anticuerpos anti grupo de diferenciacion 20 (cd20)/anti grupo de diferenciacion (cd3) biespecificos para tratar el cancer.
CN108602889A (zh) 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
EP3196646B1 (en) * 2016-01-19 2019-12-18 Hexal AG Methods of mapping protein variants
US10576128B2 (en) 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
WO2017168296A1 (en) 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
CN106279412A (zh) * 2016-09-12 2017-01-04 广东东阳光药业有限公司 一种抗vegf类单克隆抗体的纯化方法
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
EP3515487B1 (en) 2016-09-23 2023-07-19 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
JP7116059B2 (ja) 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
MY197200A (en) 2016-12-23 2023-05-31 Serum Institute Of India Pvt Ltd Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
JP7097433B2 (ja) * 2017-08-17 2022-07-07 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法
MX2020003945A (es) * 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
EP3713591A1 (en) * 2017-11-20 2020-09-30 Just-Evotec Biologics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
CN109929027B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 采用线性洗脱步骤的重组融合蛋白纯化方法
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
US11667702B2 (en) * 2018-03-08 2023-06-06 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
JP2021516672A (ja) * 2018-03-13 2021-07-08 アムジエン・インコーポレーテツド 質量分光測定分析のためのトリプシン耐性ポリペプチドを調製するための方法
BR112020022610A2 (pt) 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. proteína de fusão de receptor de vegf de alta concentração que contém formulações
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US20220098279A1 (en) 2019-01-30 2022-03-31 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
WO2020229584A1 (en) 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
JP2022550930A (ja) * 2019-12-06 2022-12-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法

Also Published As

Publication number Publication date
MX2023005421A (es) 2023-05-23
BR112021025432A2 (pt) 2022-06-21
US11542317B1 (en) 2023-01-03
US20220162289A1 (en) 2022-05-26
US11053280B2 (en) 2021-07-06
CO2021018203A2 (es) 2022-01-17
MX2022006788A (es) 2022-07-11
TW202134256A (zh) 2021-09-16
CO2022000660A2 (es) 2022-01-28
US20230331812A1 (en) 2023-10-19
AU2020398547A1 (en) 2021-10-28
IL288357B2 (en) 2023-03-01
MX2023014077A (es) 2023-12-11
US20210171605A1 (en) 2021-06-10
CA3159586A1 (en) 2021-06-10
MX2022006758A (es) 2023-01-30
BR112021025438A2 (pt) 2022-06-21
IL288355B (en) 2022-11-01
PE20221791A1 (es) 2022-11-25
IL309560A (en) 2024-02-01
US11180540B2 (en) 2021-11-23
NZ781143A (en) 2023-05-26
MY193350A (en) 2022-10-06
SG11202110958QA (en) 2021-10-28
WO2021112929A1 (en) 2021-06-10
PE20221770A1 (es) 2022-11-11
WO2021112924A1 (en) 2021-06-10
JP2022547652A (ja) 2022-11-15
IL288367A (en) 2022-01-01
US20210284684A1 (en) 2021-09-16
WO2021112926A1 (en) 2021-06-10
AU2020397803B2 (en) 2022-12-15
KR20220038348A (ko) 2022-03-28
JP2022552052A (ja) 2022-12-15
TW202128745A (zh) 2021-08-01
AU2020398547B2 (en) 2022-12-22
CN114206914A (zh) 2022-03-18
MX2021014863A (es) 2022-09-28
CA3172631A1 (en) 2021-06-10
EP3906249A1 (en) 2021-11-10
US20220009998A1 (en) 2022-01-13
US20220009999A1 (en) 2022-01-13
NZ781145A (en) 2023-05-26
US20220098280A1 (en) 2022-03-31
US11472861B2 (en) 2022-10-18
US11753459B2 (en) 2023-09-12
AU2020398830A1 (en) 2021-10-28
US20220127331A1 (en) 2022-04-28
MX2021014862A (es) 2022-09-27
EP3931204A1 (en) 2022-01-05
IL296863A (en) 2022-11-01
CO2021018234A2 (es) 2022-01-17
NZ781138A (en) 2023-05-26
US20220389081A1 (en) 2022-12-08
MY193349A (en) 2022-10-06
AU2020396490C1 (en) 2023-04-27
IL296893B1 (en) 2024-01-01
MY190686A (en) 2022-05-10
IL309491A (en) 2024-02-01
IL288355B2 (en) 2023-03-01
IL296864A (en) 2022-11-01
IL296893A (en) 2022-12-01
JP2024026116A (ja) 2024-02-28
JP2022550930A (ja) 2022-12-06
CO2021018181A2 (es) 2022-01-17
JP2023171771A (ja) 2023-12-05
BR112021025359A2 (pt) 2022-06-21
KR20230051296A (ko) 2023-04-17
SG11202110972UA (en) 2021-10-28
US11104715B2 (en) 2021-08-31
TW202122417A (zh) 2021-06-16
US12012444B2 (en) 2024-06-18
US20210206832A1 (en) 2021-07-08
SG11202110955VA (en) 2021-10-28
US20210171570A1 (en) 2021-06-10
TW202128744A (zh) 2021-08-01
US11958894B2 (en) 2024-04-16
IL288352B (en) 2022-11-01
US12054533B2 (en) 2024-08-06
US20210206833A1 (en) 2021-07-08
US11459373B2 (en) 2022-10-04
US20230119662A1 (en) 2023-04-20
MX2022006760A (es) 2023-01-30
IL302921A (en) 2023-07-01
IL288352A (en) 2022-01-01
US11299532B2 (en) 2022-04-12
IL288367B2 (en) 2023-02-01
MY193351A (en) 2022-10-06
US11174283B2 (en) 2021-11-16
JP2024009950A (ja) 2024-01-23
US11505593B2 (en) 2022-11-22
US11407813B2 (en) 2022-08-09
PE20221788A1 (es) 2022-11-25
MY190624A (en) 2022-04-27
MX2022012042A (es) 2022-10-27
US20210214733A1 (en) 2021-07-15
IL296893B2 (en) 2024-05-01
AU2020396490A1 (en) 2021-10-28
US11098311B2 (en) 2021-08-24
IL302538A (en) 2023-07-01
MY190625A (en) 2022-04-27
KR20220035393A (ko) 2022-03-22
US11548932B2 (en) 2023-01-10
AU2020398125A1 (en) 2021-10-28
EP3931303A1 (en) 2022-01-05
US12077570B2 (en) 2024-09-03
KR20220038347A (ko) 2022-03-28
MY193353A (en) 2022-10-06
BR112021025158A2 (pt) 2022-06-21
KR20240005222A (ko) 2024-01-11
KR102519236B1 (ko) 2023-04-10
SG11202110968VA (en) 2021-10-28
US20220227836A1 (en) 2022-07-21
KR20220038062A (ko) 2022-03-25
KR20240005206A (ko) 2024-01-11
US11306135B2 (en) 2022-04-19
EP3906302A1 (en) 2021-11-10
AU2020397803C1 (en) 2023-05-11
US20240309064A1 (en) 2024-09-19
CA3129193A1 (en) 2021-06-10
KR20230051297A (ko) 2023-04-17
AU2023201748A1 (en) 2023-06-01
AU2023201589A1 (en) 2023-04-06
IL296864B2 (en) 2023-10-01
US12054532B2 (en) 2024-08-06
IL288351B2 (en) 2024-05-01
US20230235019A1 (en) 2023-07-27
AU2020398830C1 (en) 2023-04-27
NZ781136A (en) 2023-05-26
BR112022001016A2 (pt) 2022-08-16
JP2023179531A (ja) 2023-12-19
US20220396608A1 (en) 2022-12-15
ZA202107644B (en) 2022-03-30
MY193354A (en) 2022-10-06
US20240067701A1 (en) 2024-02-29
US11440950B2 (en) 2022-09-13
MY193355A (en) 2022-10-06
AU2020398830B2 (en) 2022-12-15
CO2021018192A2 (es) 2022-01-17
WO2021112928A1 (en) 2021-06-10
CO2021018214A2 (es) 2022-01-17
ZA202107647B (en) 2022-03-30
BR112021025769A2 (pt) 2022-04-12
AU2020396490B2 (en) 2022-12-15
KR102619866B1 (ko) 2024-01-04
JP2022548197A (ja) 2022-11-17
WO2021112925A1 (en) 2021-06-10
CN114206925A (zh) 2022-03-18
JP2024009949A (ja) 2024-01-23
IL288357B (en) 2022-11-01
AU2023201590A1 (en) 2023-04-13
WO2021112927A1 (en) 2021-06-10
IL288355A (en) 2022-01-01
US20220048975A1 (en) 2022-02-17
AU2020397803A1 (en) 2021-10-28
AU2023201588A1 (en) 2023-04-13
IL288360B2 (en) 2023-09-01
IL296512B1 (en) 2023-08-01
US20230068199A1 (en) 2023-03-02
AU2020398547C1 (en) 2023-05-11
IL288360B1 (en) 2023-05-01
AU2023201585A1 (en) 2023-04-13
ZA202208710B (en) 2024-09-25
AU2020397865B2 (en) 2022-12-15
CN114206907A (zh) 2022-03-18
IL288360A (en) 2022-01-01
CN114423783A (zh) 2022-04-29
CN114401994A (zh) 2022-04-26
US11459374B2 (en) 2022-10-04
US20220009997A1 (en) 2022-01-13
MX2022011973A (es) 2022-11-09
IL296864B1 (en) 2023-06-01
US20220033472A1 (en) 2022-02-03
US20220033471A1 (en) 2022-02-03
IL296512B2 (en) 2023-12-01
US20220227835A1 (en) 2022-07-21
US20220275054A1 (en) 2022-09-01
PE20221261A1 (es) 2022-08-16
US20240294606A1 (en) 2024-09-05
KR20230152810A (ko) 2023-11-03
NZ781137A (en) 2023-05-26
US20230041349A1 (en) 2023-02-09
AU2020398125C1 (en) 2023-05-11
US20210214430A1 (en) 2021-07-15
JP2022547651A (ja) 2022-11-15
MY190623A (en) 2022-04-27
WO2021112923A1 (en) 2021-06-10
AU2020397865C1 (en) 2023-04-27
CN114206924A (zh) 2022-03-18
IL301888A (en) 2023-06-01
IL296863B1 (en) 2023-06-01
AU2023201586A1 (en) 2023-04-13
AU2020397865A1 (en) 2021-10-28
IL288352B2 (en) 2023-03-01
JP2024119936A (ja) 2024-09-03
US12012445B2 (en) 2024-06-18
US20210371501A1 (en) 2021-12-02
IL296512A (en) 2022-11-01
CA3172625A1 (en) 2021-06-10
KR20240007293A (ko) 2024-01-16
TW202128991A (zh) 2021-08-01
US12049489B2 (en) 2024-07-30
CA3172631C (en) 2024-01-02
IL296863B2 (en) 2023-10-01
IL288351B1 (en) 2024-01-01
KR20220038349A (ko) 2022-03-28
US11535663B2 (en) 2022-12-27
IL288357A (en) 2022-01-01
US20240317835A1 (en) 2024-09-26
IL288351A (en) 2022-01-01
PE20221789A1 (es) 2022-11-25
MY190626A (en) 2022-04-27
TW202128743A (zh) 2021-08-01
US20230272044A1 (en) 2023-08-31
US20220235116A1 (en) 2022-07-28
EP3906303A1 (en) 2021-11-10
AU2020398125B2 (en) 2022-12-15
US11485770B2 (en) 2022-11-01
US11186625B2 (en) 2021-11-30
JP2022548818A (ja) 2022-11-22
KR20220041083A (ko) 2022-03-31
US11098112B2 (en) 2021-08-24
US11286290B2 (en) 2022-03-29
US20230357357A1 (en) 2023-11-09
PE20221790A1 (es) 2022-11-25
US11505594B2 (en) 2022-11-22
CA3129193C (en) 2022-10-04
KR102519234B1 (ko) 2023-04-10
US11732025B2 (en) 2023-08-22
IL288367B (en) 2022-10-01
US11649273B2 (en) 2023-05-16
IL304390A (en) 2023-09-01
ZA202107646B (en) 2022-03-30
NZ781142A (en) 2023-05-26
MX2022006759A (es) 2023-01-30
MY190627A (en) 2022-04-27
SG11202110953UA (en) 2021-10-28
EP3906250A1 (en) 2021-11-10

Similar Documents

Publication Publication Date Title
IL304390A (en) Anti-vegf protein preparations and methods for their preparation
EP3451856A4 (en) METHOD FOR PRODUCING AND USING MYCELIED PROTEINARY FOOD COMPOSITIONS
EP3802812A4 (en) ANTI-RNA TARGETED FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
EP3824096A4 (en) NOVEL ANTIBODIES AND METHODS FOR THE PREPARATION AND USE THEREOF
EP3773718A4 (en) COMPOSITIONS AND METHODS WITH ANTI-NRP2 ANTIBODIES
IL277797A (en) Methods for preparing stable protein preparations
EP4037711A4 (en) COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES
GB202017593D0 (en) Compositions and methods and uses relating thereto
IL286587A (en) Preparations of d-methyrosine and methods for their preparation
EP3980037A4 (en) CARDIAC MYOCYTES AND COMPOSITIONS AND METHODS OF PRODUCTION THEREOF
IL290331A (en) RNA-directing ligands, preparations containing them, and methods for their preparation and use
IL285489A (en) Production of preparations containing two or more antibodies
EP3927372A4 (en) OPTIMIZED VACCINE COMPOSITIONS AND METHODS OF PRODUCTION
EP3858851A4 (en) PROTEIN COMPOSITION PRODUCTION METHOD
GB2586313B (en) Compositions and methods and uses relating thereto
AU2021401316A1 (en) Protein compositions and methods for producing and using the same
EP3638693A4 (en) IMMUNOGLOBULIN COMPOSITIONS AND PROCESS FOR THEIR PREPARATION